XORTX Therapeutics (XRTX) Total Non-Current Liabilities (2020 - 2025)
XORTX Therapeutics' (XRTX) quarterly Total Non-Current Liabilities came in at $812662.0 in Q3 2025, down 51.97% YoY from $1.7 million in Q3 2024, and up 18.34% on a QoQ basis from $686709.0 in Q2 2025.
XORTX Therapeutics (XRTX) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends
XORTX Therapeutics (XRTX) has 6 years of Total Non-Current Liabilities data on file, last reported at $812662.0 in Q3 2025.
- Quarterly Total Non-Current Liabilities fell 51.97% year-over-year to $812662.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $812662.0 (down 51.97% YoY) and the FY2024 annual result came in at $733244.0, down 8.48% from the prior year.
- Total Non-Current Liabilities rose to $812662.0 in Q3 2025, from $686709.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $9.6 million in Q3 2021 to a low of $378516.0 in Q2 2023.
- A 5-year average of $2.5 million and a median of $1.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 87.2% — and 2024, when it jumped 514.69%.
- Tracing XRTX's Total Non-Current Liabilities over 5 years: stood at $4.2 million in 2021, then grew by 27.92% to $5.3 million in 2022, then plunged by 85.01% to $801192.0 in 2023, then decreased by 8.48% to $733244.0 in 2024, then rose by 10.83% to $812662.0 in 2025.
- The last three Total Non-Current Liabilities figures came in at $812662.0 (Q3 2025), $686709.0 (Q2 2025), and $732604.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 812,662.00 |
| Jun 30, 2025 | 686,709.00 |
| Mar 31, 2025 | 732,604.00 |
| Dec 31, 2024 | 733,244.00 |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 3.53 Mn |
| Dec 31, 2023 | 801,192.00 |
| Sep 30, 2023 | 529,011.00 |
| Jun 30, 2023 | 378,516.00 |
| Mar 31, 2023 | 575,042.00 |
| Dec 31, 2022 | 5.34 Mn |
| Sep 30, 2022 | 3.24 Mn |
| Jun 30, 2022 | 2.96 Mn |
| Mar 31, 2022 | 3.95 Mn |
| Dec 31, 2021 | 4.18 Mn |
| Sep 30, 2021 | 9.56 Mn |
| Dec 31, 2020 | 768,569.60 |